HIND - NASDAQ

VH

Vyome Holdings, Inc.

HIND·NASDAQ

$5.73

+14%
HealthcareBiotechnology

Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company was founded in 2017 and is based in Princeton, New Jersey.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$151.09M
EPS-345.7400
P/E Ratio-1.29
Earnings Date05/18/2026
-4.43M
Operating Cash Flow
-74%
3Y-71.0%
5Y-69.0%
10Y-80.0%
0.00
Investing Cash Flow
-100%
3Y-100.0%
5Y-100.0%
10Y-100.0%
677.00K
Financing Cash Flow
-96%
3Y-98.0%
5Y-95.0%
10Y-96.0%
H

Vyome Holdings, Inc. Cash Conversion Engine

HIND · NASDAQ
Net Income-7.13M
Depreciation & Amortization22.00K
Stock-Based Compensation184.00K
Change in Working Capital2.29M
Others200.00K
Capital Expenditures0.00
Free Cash Flow-4.43M

Cash Flow Quality Analysis

FCF Conversion Rate

62.1%

Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.

FCF Growth Trend

+74.0%

Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.

Working Capital Impact

+$2.29M

Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.

Vyome Holdings, Inc. Cash Flow Statement

HIND • NASDAQ

Vyome Holdings, Inc. Cash Flow StatementDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015Dec 2014Dec 2013Dec 2012Dec 2011Dec 2010Dec 2009Dec 2008Dec 2007Dec 2006Dec 2005
OPERATING ACTIVITIES
Net Income
-7.1M
-11.4M
-46.2M
-35.5M
-21.6M
-74.2M
-35.3M
-33.8M
-23.4M
-25.5M
-26.1M
-25.8M
-23.5M
-26M
-17.3M
-31.9M
-37.9M
-28.6M
-17.7M
-11.2M
Depreciation & Amortization
22K
154K
2.2M
2M
1.7M
1.7M
440.6K
925.5K
139.6K
188.6K
188.9K
174.6K
227K
304K
375.8K
424.4K
513.1K
992.4K
95.8K
143.2K
Change in Deferred Taxes
6K
28K
-423K
-60K
-86K
-1.1M
-3.4M
-2.3M
1.9M
826.6K
-6.3M
199.6K
-4.2M
26.2M
440.5K
1.5M
-2.5M
0.0
0.0
0.0
Stock-Based Compensation
184K
766K
2.1M
12.2M
1.3M
2.3M
3.1M
4.4M
2.3M
6.9M
6.3M
6M
4.2M
2.9M
2.6M
2.4M
2.5M
0.0
0.0
0.0
Other Non-Cash Items
200K
-2.4M
19.8M
8.7M
10.2M
58.6M
6.8M
4.7M
-3.5M
-3.3M
6.4M
8K
4.4M
-26M
-158.8K
3.6M
3.2M
4.2M
157.8K
25K
Cash Taxes Paid
(12K)
(10K)
(5K)
(102K)
(40K)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
Change in Working Capital
2.3M
-4.1M
709K
-2.7M
6K
-1.4M
857.2K
1.4M
1.9M
-1.8M
113.4K
1M
-3.7M
2.6M
461.1K
-732.7K
515.8K
-11.1K
1.2M
768.8K
Cash from Operating Activities
-4.4M
-17M
-21.9M
-15.4M
-8.6M
-14.2M
-27.5M
-24.6M
-20.7M
-22.6M
-19.4M
-18.4M
-22.5M
-19.9M
-13.7M
-24.7M
-33.7M
-23.4M
-16.2M
-10.3M
INVESTING ACTIVITIES
Investments in Property, Plant, and Equipment
(0.0)
-43K
-131K
-352K
-390K
-14K
-49.6K
-137.1K
-14K
-38.9K
-88.7K
-416K
-76.4K
-252.3K
-2.6K
-187K
-244.4K
-800.4K
-635K
-449.8K
Acquisitions, Net
(0.0)
(0.0)
(39K)
(2.2M)
-2M
-2M
-10.3M
-6.2M
(0.0)
(6K)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
Purchase of Investments
(0.0)
(0.0)
-39K
(0.0)
(0.0)
(0.0)
-9.1M
-94.6M
-18.9M
-18.6M
(0.0)
(0.0)
(0.0)
-5M
(0.0)
(0.0)
-10.3M
-6.9M
-20M
(0.0)
Sale/Maturity of Investments
0.0
0.0
639K
0.0
0.0
2.6M
29.9M
73.8M
25.5M
21.5M
0.0
0.0
1M
4M
0.0
5.2M
13.4M
16M
3M
0.0
Other Investing Items
0.0
33K
-600K
0.0
0.0
-2.6M
-20.8M
20.8M
-6.6M
0.0
0.0
200K
1M
6.3M
-6.5M
0.0
0.0
0.0
0.0
0.0
Cash from Investing Activities
(0.0)
-10K
-92K
(1.9M)
-2.4M
-2M
-10.3M
-6.4M
-14K
-38.9K
-88.7K
-216K
(923.6K)
(5.1M)
-6.5M
(5M)
(2.8M)
(8.2M)
-17.7M
-449.8K
FINANCING ACTIVITIES
Net Issuance of Common Stock
24K
17.6M
639K
42.8M
679K
478K
37.7M
6.5M
0.0
22.7M
9.8M
24.1M
5.1M
14.5M
32.5M
-899K
0.0
40.9M
40.9M
7.8M
Net Issuance of Debt
653K
0.0
0.0
-9.5M
10.5M
0.0
0.0
0.0
16.8M
5M
-4M
-3M
4.6M
-922K
-1.9M
-6.8M
3.3M
7.2M
1.3M
8.4M
Share Repurchases
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
-1.2M
-2.6M
-899K
(0.0)
(0.0)
(0.0)
(0.0)
Other Financing Items
0.0
0.0
2.5M
0.0
-59K
13.2M
-4M
31.3M
-749.8K
-8.7M
2M
-1.4M
5.7M
-1.1M
23.7K
20.9M
-164.8K
-1.8M
-1.5M
-40.1K
Cash from Financing Activities
677K
17.6M
3.1M
33.3M
11.1M
13.7M
33.2M
37.8M
16.1M
19M
7.8M
19.6M
15.4M
12.5M
36.4M
13.2M
3.2M
46.3M
40.7M
16.1M
CASH FLOW SUMMARY
Effect of Foreign Exchange Rates
-16K
0.0
4K
29K
-113K
-8K
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net Change in Cash
-3.8M
604K
-18.9M
19.8M
22K
-2.6M
-4.6M
6.9M
-4.6M
-3.7M
-11.7M
988.7K
-6.2M
-2.4M
16.2M
-6.4M
-27.7M
31.2M
6.8M
5.4M
Cash at Beginning of Period
4.6M
4M
22.8M
3M
3M
5.5M
10.2M
3.3M
7.9M
11.6M
23.3M
22.3M
28.5M
30.8M
14.6M
21.1M
48.7M
17.5M
10.7M
5.3M
Cash at End of Period
793K
4.6M
4M
22.8M
3M
3M
5.5M
10.2M
3.3M
7.9M
11.6M
23.3M
22.3M
28.5M
30.8M
14.6M
21.1M
48.7M
17.5M
10.7M
Free Cash Flow
-4.4M
-17M
-22M
-15.7M
-8.9M
-14.2M
-27.5M
-24.7M
-20.7M
-22.6M
-19.5M
-18.8M
-22.6M
-20.2M
-13.7M
-24.8M
-33.9M
-24.2M
-16.9M
-10.7M

SEC Filings

HIND - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
8-K

8-K 2025

N/A

November 19, 2025
November 18, 2025
2025
View Filing
10-Q

10-Q 2025 Q3

Q3

November 14, 2025
September 30, 2025
2025
View Filing
S-3

S-3

N/A

November 06, 2025
November 06, 2025
 
View Filing
8-K

8-K 2025

N/A

October 30, 2025
October 28, 2025
2025
View Filing
DEF 14A

DEF 14A 2025

N/A

October 06, 2025
October 28, 2025
2025
View Filing
8-K

8-K 2025

N/A

October 03, 2025
September 29, 2025
2025
View Filing
8-K/A

8-K/A 2025 (Amended)

N/A

September 12, 2025
September 02, 2025
2025
View Filing
8-K

8-K 2025

N/A

September 02, 2025
September 02, 2025
2025
View Filing
8-K

8-K 2025

N/A

August 20, 2025
August 18, 2025
2025
View Filing
8-K

8-K 2025

N/A

August 19, 2025
August 13, 2025
2025
View Filing
Showing 1 to 10 of 233 filings

Related Guides

Blog Categories

Continue your HIND research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.